- Home
- FULC
as 08-11-2025 9:50am EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 375.4M | IPO Year: | 2019 |
| Target Price: | $7.13 | AVG Volume (30 days): | 984.6K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $10.13 | Next Earning Date: | 07-29-2025 |
| Revenue: | N/A | Revenue Growth: | 2752.05% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Fulcrum Therapeutics (NASDAQ:FULC) investors are sitting on a loss of 60% if they invested five years ago
GlobeNewswire
2 months ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
2 months ago
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
GlobeNewswire
2 months ago
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
GlobeNewswire
2 months ago
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
MT Newswires
3 months ago
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink
MT Newswires
3 months ago
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4
MT Newswires
3 months ago
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.